Gyre Therapeutics (GYRE) EBITDA Margin (2010 - 2026)
Gyre Therapeutics' EBITDA Margin came in at -44.25% for Q2 2026, down 40.11 percentage points from -4.14% a year earlier and down 5.70 percentage points from the prior quarter.
Powered by 
Analysis
Gyre Therapeutics (GYRE) EBITDA Margin (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Gyre Therapeutics reported EBITDA Margin of -11.38%, down 18.40 percentage points year-over-year; for FY2025, it was 11.98%, down 4.77 percentage points from FY2024.
- EBITDA Margin carries a five-year change of +285.19 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was 16.75% in FY2024 (+75.06 pp), -58.31% in FY2023 (-68.37 pp), 10.06% in FY2022 (+1203.90 pp) and -1193.84% in FY2021 (-920.63 pp).
- The Q2 2026 figure represents the lowest quarterly EBITDA Margin since Q4 2023.
- Year-over-year, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of +24.26 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q1 2023 (a gain of 1865.12 percentage points), and the weakest in Q4 2023 (a drop of 315.16 percentage points).
- Business Quant data shows GYRE's EBITDA Margin at -38.56% (Q1 2026), 2.08% (Q4 2025) and 23.58% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 39.10% |
| 10 | Gyre Therapeutics | 777.23 Mn | 579.94 Mn | 26.90 Mn | -44.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.25% |
| Mar 31, 2026 | -38.56% |
| Dec 31, 2025 | 2.08% |
| Sep 30, 2025 | 23.58% |
| Jun 30, 2025 | -4.14% |
| Mar 31, 2025 | 12.73% |
| Dec 31, 2024 | 4.04% |
| Sep 30, 2024 | 18.35% |
| Jun 30, 2024 | 13.57% |
| Mar 31, 2024 | 31.23% |
| Dec 31, 2023 | -336.43% |
| Sep 30, 2023 | 40.43% |
| Jun 30, 2023 | 18.01% |
| Mar 31, 2023 | 27.84% |
| Dec 31, 2022 | -21.27% |
| Mar 31, 2022 | -1,837.28% |
| Dec 31, 2021 | -827.79% |
| Sep 30, 2021 | -1,093.69% |
| Jun 30, 2021 | -1,755.21% |
| Mar 31, 2021 | -1,526.45% |
API Access
Gyre Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GYRE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "GYRE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GYRE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();